Vical is based in Sorrento Mesa. It's now a partner of the U.S. Naval Medical Research Center to bring an H1N1 vaccine into clinical trials as quickly as possible.
Vical says it could make a shot available in six to nine weeks because it produces a vaccine using DNA technology not chicken eggs.
Vical says it's excited to work with the navy.
"We have a lot of synergistic relationship with the Navy. The Navy understands what our core competencies are, and we know the Navy's expertise is...so this is a great collaboration," said VICAL President and CEO Vijay Samant.
Vical is also working with the Navy on a dengue fever vaccine.